Alexion Pharmaceuticals, Inc. (ALXN) Holdings Raised by LS Investment Advisors LLC

LS Investment Advisors LLC raised its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 1.4% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,689 shares of the biopharmaceutical company’s stock after purchasing an additional 94 shares during the quarter. LS Investment Advisors LLC’s holdings in Alexion Pharmaceuticals were worth $904,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Standard Life Aberdeen plc grew its position in shares of Alexion Pharmaceuticals by 10.9% in the 3rd quarter. Standard Life Aberdeen plc now owns 69,872 shares of the biopharmaceutical company’s stock worth $9,712,000 after acquiring an additional 6,873 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of Alexion Pharmaceuticals in the 3rd quarter worth approximately $9,439,000. Kentucky Retirement Systems acquired a new position in shares of Alexion Pharmaceuticals in the 3rd quarter worth approximately $2,154,000. Neuberger Berman Group LLC grew its position in shares of Alexion Pharmaceuticals by 11.7% in the 3rd quarter. Neuberger Berman Group LLC now owns 585,888 shares of the biopharmaceutical company’s stock worth $81,445,000 after acquiring an additional 61,309 shares in the last quarter. Finally, Legal & General Group Plc grew its position in shares of Alexion Pharmaceuticals by 1.4% in the 3rd quarter. Legal & General Group Plc now owns 960,726 shares of the biopharmaceutical company’s stock worth $133,550,000 after acquiring an additional 13,631 shares in the last quarter. Hedge funds and other institutional investors own 94.83% of the company’s stock.

Shares of NASDAQ ALXN opened at $134.57 on Monday. The company has a market capitalization of $30.07 billion, a P/E ratio of 18.98, a P/E/G ratio of 1.03 and a beta of 1.55. Alexion Pharmaceuticals, Inc. has a 12-month low of $92.56 and a 12-month high of $141.86. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.48 and a current ratio of 3.87.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.40. The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.13 billion. Alexion Pharmaceuticals had a return on equity of 19.53% and a net margin of 9.59%. The business’s revenue was up 22.5% on a year-over-year basis. During the same quarter last year, the business posted $1.68 EPS. On average, research analysts forecast that Alexion Pharmaceuticals, Inc. will post 8.52 earnings per share for the current year.

Several research analysts have recently commented on the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $186.00 target price (up previously from $165.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, March 27th. TheStreet upgraded Alexion Pharmaceuticals from a “c” rating to a “b” rating in a research report on Thursday. BidaskClub lowered Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 21st. Raymond James assumed coverage on Alexion Pharmaceuticals in a research report on Wednesday, April 10th. They issued an “outperform” rating and a $161.00 target price for the company. Finally, Zacks Investment Research lowered Alexion Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 31st. Six analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $162.25.

In related news, CAO Daniel Bazarko sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 14th. The stock was sold at an average price of $126.00, for a total value of $252,000.00. Following the sale, the chief accounting officer now owns 5,020 shares of the company’s stock, valued at approximately $632,520. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 4.08% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Alexion Pharmaceuticals, Inc. (ALXN) Holdings Raised by LS Investment Advisors LLC” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://sportsperspectives.com/2019/04/29/alexion-pharmaceuticals-inc-alxn-holdings-raised-by-ls-investment-advisors-llc.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Recommended Story: Options Trading – Understanding Strike Price

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.